Biomerica expects Completion of Patient Enrollment for its InFoods® Diagnostic-Guided Therapy Irritable Bowel Syndrome Clinical Trial this week
30 août 2021 08h19 HE
|
Biomerica, Inc.
Final patients to compete this double blinded trial by end of October. Top-Line trial results expected by year end.The InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind for...
Biomerica Receives Notice of Allowance from Mexican Patent Office for Irritable Bowel Syndrome Food Sensitivity Testing & Treatment
15 juin 2021 08h19 HE
|
Biomerica, Inc.
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients)Broadens InFoods® global patent coverage with recently...
Biomerica Reports 208% Increase In Q3 Fiscal 2021 Sales, Over Q3 Fiscal 2020
15 avr. 2021 10h31 HE
|
Biomerica, Inc.
Sales increase driven by first sales of COVID-19 Antigen Rapid Test in Europe after January 2021 CE Mark approval Awarded two new patents for InFoods® diagnostic guided therapy technology, including...
Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors
31 août 2020 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced today the retirement of Janet Moore, the Company’s Chief Financial Officer. After many years of...
Biomerica Announces Second Quarter Financial Results; Sales Up 6.4% for the Quarter
15 janv. 2020 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the...
Houston Methodist (part of Texas Medical Center) to start patient enrollment for Biomerica’s InFoods® Irritable Bowel Syndrome (IBS) diagnostic guided therapy clinical trial
07 janv. 2020 08h19 HE
|
Biomerica, Inc.
Texas Medical Center is the largest medical complex in the world with 10 million patient encounters per year and a 1,345-acre campus (50 million square feet of developed facilities)InFoods® Diagnostic...
Biomerica Announces Fiscal Year End 2019 Financial Results
30 août 2019 08h30 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
Biomerica Announces Notice of Allowance for New U.S. Patent Application Covering Diagnostic Guided Therapy for Irritable Bowel Syndrome (IBS)
08 avr. 2019 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for...
Biomerica Receives Notice of Allowance for Irritable Bowel Syndrome (IBS) Test Panel and Methods in Korea
02 août 2018 08h19 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq:BMRA) announced today that the Korean Intellectual Property Office (KIPO) has issued a Notice of Allowance for a patent...
Biomerica Announces First Patient Enrollment in Clinical Study for New Irritable Bowel Syndrome (IBS) Diagnostic Guided Therapy
25 juin 2018 08h19 HE
|
Biomerica, Inc.
Diagnostic Guided Therapy (DGT) is designed to identify patient specific foods, that when removed, may alleviate an individual's IBS symptomsApproximately 45 million Americans suffer from IBS1 Studies...